
PMC:7187660 / 69-3772
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 66-74 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 502-510 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 603-611 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T5 | 614-623 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T6 | 841-849 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 1139-1161 | Disease | denotes | cardiovascular disease | http://purl.obolibrary.org/obo/MONDO_0004995 |
T8 | 1205-1217 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T9 | 1261-1269 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
T10 | 1313-1332 | Disease | denotes | respiratory disease | http://purl.obolibrary.org/obo/MONDO_0005087 |
T11 | 1483-1491 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T12 | 1558-1566 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T13 | 2398-2410 | Disease | denotes | Hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T14 | 2479-2487 | Disease | denotes | Diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
T15 | 2553-2575 | Disease | denotes | Cardiovascular disease | http://purl.obolibrary.org/obo/MONDO_0004995 |
T16 | 2640-2659 | Disease | denotes | Respiratory disease | http://purl.obolibrary.org/obo/MONDO_0005087 |
T17 | 2722-2728 | Disease | denotes | Cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T18 | 3061-3069 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 84-87 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T2 | 93-94 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T3 | 359-361 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T4 | 544-545 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T5 | 671-673 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T6 | 1001-1005 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T7 | 1001-1005 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
T8 | 1053-1059 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | female |
T9 | 1742-1745 | http://purl.obolibrary.org/obo/CLO_0001414 | denotes | 548 |
T10 | 1817-1819 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
T11 | 2247-2251 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | Male |
T12 | 2247-2251 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | Male |
T13 | 2324-2330 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | Female |
T14 | 2660-2663 | http://purl.obolibrary.org/obo/CLO_0001405 | denotes | 511 |
T15 | 2849-2852 | http://purl.obolibrary.org/obo/CLO_0001445 | denotes | 617 |
T16 | 2958-2959 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T17 | 2973-2974 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T18 | 3097-3101 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T19 | 3097-3101 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
T20 | 3115-3116 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T21 | 3159-3165 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | female |
T22 | 3236-3237 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T23 | 3496-3497 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T24 | 3596-3600 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T25 | 3596-3600 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 1001-1005 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
T2 | 1070-1072 | Chemical | denotes | RR | http://purl.obolibrary.org/obo/CHEBI_73811 |
T3 | 1163-1165 | Chemical | denotes | RR | http://purl.obolibrary.org/obo/CHEBI_73811 |
T4 | 1271-1273 | Chemical | denotes | RR | http://purl.obolibrary.org/obo/CHEBI_73811 |
T5 | 1334-1336 | Chemical | denotes | RR | http://purl.obolibrary.org/obo/CHEBI_73811 |
T6 | 1389-1391 | Chemical | denotes | RR | http://purl.obolibrary.org/obo/CHEBI_73811 |
T7 | 1663-1665 | Chemical | denotes | RR | http://purl.obolibrary.org/obo/CHEBI_73811 |
T8 | 2823-2828 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T9 | 2874-2879 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T10 | 2909-2914 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T11 | 3097-3101 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
T12 | 3596-3600 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 0-160 | Sentence | denotes | Using meta-analysis to explore clinical determinants for death of COVID-19 patients has been a problem due to insufficient sample size and overlapped cases [1]. |
T3 | 161-434 | Sentence | denotes | In the study, we re-analyzed the largest confirmed case series reported publicly by the Chinese center for disease control and prevention (44,672 laboratory confirmed cases updated through February 11, 2020, [2]), to explore the clinical risk factors associated with death. |
T4 | 435-537 | Sentence | denotes | The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1. |
T5 | 538-707 | Sentence | denotes | Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up. |
T6 | 708-822 | Sentence | denotes | The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a). |
T7 | 823-970 | Sentence | denotes | The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3]. |
T8 | 971-1125 | Sentence | denotes | Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p < 0.001) (see Fig. 1b). |
T9 | 1126-1492 | Sentence | denotes | Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p < 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p < 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p < 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p < 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19. |
T10 | 1493-1566 | Sentence | denotes | Table 1 Characteristics between survivors and non-survivors with COVID-19 |
T11 | 1567-1675 | Sentence | denotes | Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p |
T12 | 1676-1686 | Sentence | denotes | Age, n (%) |
T13 | 1687-1716 | Sentence | denotes | 0– 416 (0.9%) 0 416 (0.9%) 0 |
T14 | 1717-1756 | Sentence | denotes | 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2 |
T15 | 1757-1798 | Sentence | denotes | 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2 |
T16 | 1799-1843 | Sentence | denotes | 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2 |
T17 | 1844-1888 | Sentence | denotes | 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4 |
T18 | 1889-1937 | Sentence | denotes | 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3 |
T19 | 1938-1984 | Sentence | denotes | 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6 |
T20 | 1985-2029 | Sentence | denotes | 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0 |
T21 | 2030-2076 | Sentence | denotes | ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8 |
T22 | 2077-2093 | Sentence | denotes | Severity*, n (%) |
T23 | 2094-2142 | Sentence | denotes | Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0 |
T24 | 2143-2180 | Sentence | denotes | Severe 6168 (13.8%) 0 6168 (14.1%) 0 |
T25 | 2181-2231 | Sentence | denotes | Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0 |
T26 | 2232-2245 | Sentence | denotes | Gender, n (%) |
T27 | 2246-2322 | Sentence | denotes | Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) < 0.001 |
T28 | 2323-2376 | Sentence | denotes | Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7 |
T29 | 2377-2396 | Sentence | denotes | Comorbidity#, n (%) |
T30 | 2397-2477 | Sentence | denotes | Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) < 0.001 |
T31 | 2478-2551 | Sentence | denotes | Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) < 0.001 |
T32 | 2552-2638 | Sentence | denotes | Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) < 0.001 |
T33 | 2639-2720 | Sentence | denotes | Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) < 0.001 |
T34 | 2721-2786 | Sentence | denotes | Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006 |
T35 | 2787-2829 | Sentence | denotes | *Missing data (n = 257 in survivors group) |
T36 | 2830-2915 | Sentence | denotes | #Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group) |
T37 | 2916-2989 | Sentence | denotes | Fig. 1 Fatality rate distribution of age (a) and gender (b). ***p < 0.001 |
T38 | 2990-3175 | Sentence | denotes | In summary, we found that there was no difference in the prevalence of COVID-19 between men and women, but male patients had a nearly 1.7-fold higher risk of death than female patients. |
T39 | 3176-3268 | Sentence | denotes | Moreover, we concluded that patients with comorbidities had a significantly high death risk. |
T40 | 3269-3470 | Sentence | denotes | Admittedly, due to the unavailability of individual patient data, we could not exclude the influence of age on the conclusion because old patients were more likely to have the underlying comorbidities. |
T41 | 3471-3639 | Sentence | denotes | We would like to provide a reminder to the physicians that more intensive surveillance or treatment should be considered for male patients and those with comorbidities. |
T42 | 3640-3703 | Sentence | denotes | Further and larger studies are needed to validate the findings. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 1139-1161 | Phenotype | denotes | cardiovascular disease | http://purl.obolibrary.org/obo/HP_0001626 |
T2 | 1205-1217 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T3 | 2398-2410 | Phenotype | denotes | Hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T4 | 2553-2575 | Phenotype | denotes | Cardiovascular disease | http://purl.obolibrary.org/obo/HP_0001626 |
T5 | 2722-2728 | Phenotype | denotes | Cancer | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 57-62 | GO:0016265 | denotes | death |
T3 | 66-74 | SP_7 | denotes | COVID-19 |
T4 | 276-283 | GO:0065007 | denotes | control |
T5 | 428-433 | GO:0016265 | denotes | death |
T6 | 502-510 | SP_7 | denotes | COVID-19 |
T7 | 603-613 | SP_7 | denotes | SARS-CoV-2 |
T8 | 841-849 | SP_7 | denotes | COVID-19 |
T9 | 1139-1153 | UBERON:0004535 | denotes | cardiovascular |
T10 | 1313-1324 | UBERON:0001004 | denotes | respiratory |
T11 | 1483-1491 | SP_7 | denotes | COVID-19 |
T12 | 1558-1588 | SP_7 | denotes | COVID-19 Characteristics Total |
T13 | 2553-2567 | UBERON:0004535 | denotes | Cardiovascular |
T15 | 3061-3069 | SP_7 | denotes | COVID-19 |
T16 | 3148-3153 | GO:0016265 | denotes | death |
T17 | 3257-3262 | GO:0016265 | denotes | death |
T18 | 3545-3557 | GO:0065007 | denotes | surveillance |
T14874 | 57-62 | GO:0016265 | denotes | death |
T65338 | 66-74 | SP_7 | denotes | COVID-19 |
T80647 | 276-283 | GO:0065007 | denotes | control |
T90898 | 428-433 | GO:0016265 | denotes | death |
T89898 | 502-510 | SP_7 | denotes | COVID-19 |
T58247 | 603-613 | SP_7 | denotes | SARS-CoV-2 |
T56005 | 841-849 | SP_7 | denotes | COVID-19 |
T25359 | 1139-1153 | UBERON:0004535 | denotes | cardiovascular |
T45386 | 1313-1324 | UBERON:0001004 | denotes | respiratory |
T24778 | 1483-1491 | SP_7 | denotes | COVID-19 |
T56769 | 1558-1588 | SP_7 | denotes | COVID-19 Characteristics Total |
T38161 | 2553-2567 | UBERON:0004535 | denotes | Cardiovascular |
T89260 | 3061-3069 | SP_7 | denotes | COVID-19 |
T78176 | 3148-3153 | GO:0016265 | denotes | death |
T31503 | 3257-3262 | GO:0016265 | denotes | death |
T26047 | 3545-3557 | GO:0065007 | denotes | surveillance |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
8 | 75-83 | Species | denotes | patients | Tax:9606 |
9 | 57-62 | Disease | denotes | death | MESH:D003643 |
10 | 66-74 | Disease | denotes | COVID-19 | MESH:C000657245 |
11 | 428-433 | Disease | denotes | death | MESH:D003643 |
17 | 2398-2410 | Disease | denotes | Hypertension | MESH:D006973 |
18 | 2479-2487 | Disease | denotes | Diabetes | MESH:D003920 |
19 | 2553-2575 | Disease | denotes | Cardiovascular disease | MESH:D002318 |
20 | 2640-2659 | Disease | denotes | Respiratory disease | MESH:D012140 |
21 | 2722-2728 | Disease | denotes | Cancer | MESH:D009369 |
23 | 1558-1566 | Disease | denotes | COVID-19 | MESH:C000657245 |
41 | 562-570 | Species | denotes | patients | Tax:9606 |
42 | 637-645 | Species | denotes | patients | Tax:9606 |
43 | 775-783 | Species | denotes | patients | Tax:9606 |
44 | 858-861 | Species | denotes | men | Tax:9606 |
45 | 866-871 | Species | denotes | women | Tax:9606 |
46 | 1006-1014 | Species | denotes | patients | Tax:9606 |
47 | 1060-1068 | Species | denotes | patients | Tax:9606 |
48 | 1469-1477 | Species | denotes | patients | Tax:9606 |
49 | 502-510 | Disease | denotes | COVID-19 | MESH:C000657245 |
50 | 603-623 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
51 | 841-849 | Disease | denotes | COVID-19 | MESH:C000657245 |
52 | 1139-1161 | Disease | denotes | cardiovascular disease | MESH:D002318 |
53 | 1205-1217 | Disease | denotes | hypertension | MESH:D006973 |
54 | 1261-1269 | Disease | denotes | diabetes | MESH:D003920 |
55 | 1313-1332 | Disease | denotes | respiratory disease | MESH:D012140 |
56 | 1380-1387 | Disease | denotes | cancers | MESH:D009369 |
57 | 1483-1491 | Disease | denotes | COVID-19 | MESH:C000657245 |
69 | 3078-3081 | Species | denotes | men | Tax:9606 |
70 | 3086-3091 | Species | denotes | women | Tax:9606 |
71 | 3102-3110 | Species | denotes | patients | Tax:9606 |
72 | 3166-3174 | Species | denotes | patients | Tax:9606 |
73 | 3204-3212 | Species | denotes | patients | Tax:9606 |
74 | 3321-3328 | Species | denotes | patient | Tax:9606 |
75 | 3407-3415 | Species | denotes | patients | Tax:9606 |
76 | 3601-3609 | Species | denotes | patients | Tax:9606 |
77 | 3061-3069 | Disease | denotes | COVID-19 | MESH:C000657245 |
78 | 3148-3153 | Disease | denotes | death | MESH:D003643 |
79 | 3257-3262 | Disease | denotes | death | MESH:D003643 |